Natco Pharma launches Valsartan Sacubitril tablets in India under brand name VALSAC
Valsartan Sacubitril is a combination drug used for certain types of heart failure and works by relaxing blood vessels, making it easier for the heart to pump blood to the body.
Hyderabad: Soon after diversifying its portfolio by entering into agrichemical space, the Hyderabad based Natco Pharma Limited has announced the launch of Valsartan-Sacubitril tablet, under its brand VALSAC.
NATCO has launched VALSAC in 50 mg & 100 mg strengths at an MRP of INR 45.0 and INR 55.0, per tablet, respectively.
Valsartan-Sacubitril is a combination drug used for certain types of heart failure and works by relaxing blood vessels, making it easier for the heart to pump blood to the body.
Valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. While Sacubitril is an antihypertensive drug used in combination with valsartan.
Also Read:EU cracks down on Valsartan- blood pressure medicine made by Mylan
The firm has recently diversified its portfolio by entering into agrichemical space and initiated work on it green-field manufacturing facilities for producing niche products in that area in Nellore District of Andhra Pradesh. The facility will manufacture both agrichemical technical and formulation products. Natco expects the facilities to be commissioned by the end of 2019 with a total capital expenditure of Rs 100 crore.
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of Rs 3.3 million. The firm has seven manufacturing facilities spread across India with modern research laboratories. It is involved in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd